1650 related articles for article (PubMed ID: 12075054)
21. Novel Insights Into the Long-Term Immune Health of Diffuse Large B-Cell Lymphoma Survivors.
Morton LM
J Clin Oncol; 2020 May; 38(15):1648-1650. PubMed ID: 32228357
[No Abstract] [Full Text] [Related]
22. Retracted: Analysis of the Correlation of Basic Fibroblast Growth Factor in Serum of Patients with Diffuse Large B-Cell Lymphoma with Clinicopathological Efficacy and International Prognostic Index.
Imaging CMM
Contrast Media Mol Imaging; 2023; 2023():9828072. PubMed ID: 37810489
[TBL] [Abstract][Full Text] [Related]
23. Validation of LymphGen classification on a 400-gene clinical next-generation sequencing panel in diffuse large B-cell lymphoma: real-world experience from a cancer center.
Zhu ML; Drill E; Joffe E; Salles G; Delgado AR; Zelenetz A; Palomba ML; Arcila M; Dogan A
Haematologica; 2024 Mar; ():. PubMed ID: 38497151
[TBL] [Abstract][Full Text] [Related]
24. Genotyping on circulating tumor DNA improves mutation detection rate in high-risk diffuse large B-cell lymphoma.
Xia Y; Wang L; Liang J; Shen H; Wu J; Yin H; Li Y; Zhu H; Li J; Xu W
Genes Dis; 2024 Jul; 11(4):101116. PubMed ID: 38515934
[No Abstract] [Full Text] [Related]
25. Correction to: Mortality among patients with diffuse large B-cell lymphoma and mental disorders: a population-based study.
J Natl Cancer Inst; 2023 Nov; 115(11):1436. PubMed ID: 37740939
[No Abstract] [Full Text] [Related]
26. Correction for Scuoppo et al., Repurposing dasatinib for diffuse large B cell lymphoma.
Proc Natl Acad Sci U S A; 2024 Jan; 121(4):e2321988121. PubMed ID: 38227673
[No Abstract] [Full Text] [Related]
27. Stromal gene signatures in large-B-cell lymphomas.
Lenz G; Wright G; Dave SS; Xiao W; Powell J; Zhao H; Xu W; Tan B; Goldschmidt N; Iqbal J; Vose J; Bast M; Fu K; Weisenburger DD; Greiner TC; Armitage JO; Kyle A; May L; Gascoyne RD; Connors JM; Troen G; Holte H; Kvaloy S; Dierickx D; Verhoef G; Delabie J; Smeland EB; Jares P; Martinez A; Lopez-Guillermo A; Montserrat E; Campo E; Braziel RM; Miller TP; Rimsza LM; Cook JR; Pohlman B; Sweetenham J; Tubbs RR; Fisher RI; Hartmann E; Rosenwald A; Ott G; Muller-Hermelink HK; Wrench D; Lister TA; Jaffe ES; Wilson WH; Chan WC; Staudt LM;
N Engl J Med; 2008 Nov; 359(22):2313-23. PubMed ID: 19038878
[TBL] [Abstract][Full Text] [Related]
28. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray.
Hans CP; Weisenburger DD; Greiner TC; Gascoyne RD; Delabie J; Ott G; Müller-Hermelink HK; Campo E; Braziel RM; Jaffe ES; Pan Z; Farinha P; Smith LM; Falini B; Banham AH; Rosenwald A; Staudt LM; Connors JM; Armitage JO; Chan WC
Blood; 2004 Jan; 103(1):275-82. PubMed ID: 14504078
[TBL] [Abstract][Full Text] [Related]
29. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma.
Wright G; Tan B; Rosenwald A; Hurt EH; Wiestner A; Staudt LM
Proc Natl Acad Sci U S A; 2003 Aug; 100(17):9991-6. PubMed ID: 12900505
[TBL] [Abstract][Full Text] [Related]
30. ABC, GCB, and Double-Hit Diffuse Large B-Cell Lymphoma: Does Subtype Make a Difference in Therapy Selection?
Nowakowski GS; Czuczman MS
Am Soc Clin Oncol Educ Book; 2015; ():e449-57. PubMed ID: 25993209
[TBL] [Abstract][Full Text] [Related]
31. Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways.
Lenz G; Wright GW; Emre NC; Kohlhammer H; Dave SS; Davis RE; Carty S; Lam LT; Shaffer AL; Xiao W; Powell J; Rosenwald A; Ott G; Muller-Hermelink HK; Gascoyne RD; Connors JM; Campo E; Jaffe ES; Delabie J; Smeland EB; Rimsza LM; Fisher RI; Weisenburger DD; Chan WC; Staudt LM
Proc Natl Acad Sci U S A; 2008 Sep; 105(36):13520-5. PubMed ID: 18765795
[TBL] [Abstract][Full Text] [Related]
32. Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue.
Scott DW; Wright GW; Williams PM; Lih CJ; Walsh W; Jaffe ES; Rosenwald A; Campo E; Chan WC; Connors JM; Smeland EB; Mottok A; Braziel RM; Ott G; Delabie J; Tubbs RR; Cook JR; Weisenburger DD; Greiner TC; Glinsmann-Gibson BJ; Fu K; Staudt LM; Gascoyne RD; Rimsza LM
Blood; 2014 Feb; 123(8):1214-7. PubMed ID: 24398326
[TBL] [Abstract][Full Text] [Related]
33. A predictive model for aggressive non-Hodgkin's lymphoma.
International Non-Hodgkin's Lymphoma Prognostic Factors Project
N Engl J Med; 1993 Sep; 329(14):987-94. PubMed ID: 8141877
[TBL] [Abstract][Full Text] [Related]
34. A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy.
Choi WW; Weisenburger DD; Greiner TC; Piris MA; Banham AH; Delabie J; Braziel RM; Geng H; Iqbal J; Lenz G; Vose JM; Hans CP; Fu K; Smith LM; Li M; Liu Z; Gascoyne RD; Rosenwald A; Ott G; Rimsza LM; Campo E; Jaffe ES; Jaye DL; Staudt LM; Chan WC
Clin Cancer Res; 2009 Sep; 15(17):5494-502. PubMed ID: 19706817
[TBL] [Abstract][Full Text] [Related]
35. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma.
Wilson WH; Young RM; Schmitz R; Yang Y; Pittaluga S; Wright G; Lih CJ; Williams PM; Shaffer AL; Gerecitano J; de Vos S; Goy A; Kenkre VP; Barr PM; Blum KA; Shustov A; Advani R; Fowler NH; Vose JM; Elstrom RL; Habermann TM; Barrientos JC; McGreivy J; Fardis M; Chang BY; Clow F; Munneke B; Moussa D; Beaupre DM; Staudt LM
Nat Med; 2015 Aug; 21(8):922-6. PubMed ID: 26193343
[TBL] [Abstract][Full Text] [Related]
36. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma.
Davis RE; Ngo VN; Lenz G; Tolar P; Young RM; Romesser PB; Kohlhammer H; Lamy L; Zhao H; Yang Y; Xu W; Shaffer AL; Wright G; Xiao W; Powell J; Jiang JK; Thomas CJ; Rosenwald A; Ott G; Muller-Hermelink HK; Gascoyne RD; Connors JM; Johnson NA; Rimsza LM; Campo E; Jaffe ES; Wilson WH; Delabie J; Smeland EB; Fisher RI; Braziel RM; Tubbs RR; Cook JR; Weisenburger DD; Chan WC; Pierce SK; Staudt LM
Nature; 2010 Jan; 463(7277):88-92. PubMed ID: 20054396
[TBL] [Abstract][Full Text] [Related]
37. The 2016 revision of the World Health Organization classification of lymphoid neoplasms.
Swerdlow SH; Campo E; Pileri SA; Harris NL; Stein H; Siebert R; Advani R; Ghielmini M; Salles GA; Zelenetz AD; Jaffe ES
Blood; 2016 May; 127(20):2375-90. PubMed ID: 26980727
[TBL] [Abstract][Full Text] [Related]
38. Oncogenically active MYD88 mutations in human lymphoma.
Ngo VN; Young RM; Schmitz R; Jhavar S; Xiao W; Lim KH; Kohlhammer H; Xu W; Yang Y; Zhao H; Shaffer AL; Romesser P; Wright G; Powell J; Rosenwald A; Muller-Hermelink HK; Ott G; Gascoyne RD; Connors JM; Rimsza LM; Campo E; Jaffe ES; Delabie J; Smeland EB; Fisher RI; Braziel RM; Tubbs RR; Cook JR; Weisenburger DD; Chan WC; Staudt LM
Nature; 2011 Feb; 470(7332):115-9. PubMed ID: 21179087
[TBL] [Abstract][Full Text] [Related]
39. Prognostic Significance of Diffuse Large B-Cell Lymphoma Cell of Origin Determined by Digital Gene Expression in Formalin-Fixed Paraffin-Embedded Tissue Biopsies.
Scott DW; Mottok A; Ennishi D; Wright GW; Farinha P; Ben-Neriah S; Kridel R; Barry GS; Hother C; Abrisqueta P; Boyle M; Meissner B; Telenius A; Savage KJ; Sehn LH; Slack GW; Steidl C; Staudt LM; Connors JM; Rimsza LM; Gascoyne RD
J Clin Oncol; 2015 Sep; 33(26):2848-56. PubMed ID: 26240231
[TBL] [Abstract][Full Text] [Related]
40. Diffuse large B-cell lymphoma-treatment approaches in the molecular era.
Roschewski M; Staudt LM; Wilson WH
Nat Rev Clin Oncol; 2014 Jan; 11(1):12-23. PubMed ID: 24217204
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
